Related Experiment Video

Updated: Aug 29, 2025

Assaying Protein Kinase Activity with Radiolabeled ATP
08:05

Assaying Protein Kinase Activity with Radiolabeled ATP

Published on: May 26, 2017

18.5K

U0126: Not only a MAPK kinase inhibitor

Yijie You1, Yunlian Niu2, Jian Zhang1

  • 1Department of Neurosurgery, Xinhua Hospital Chongming Branch, Shanghai, China.

Frontiers in Pharmacology
|September 12, 2022
PubMed

Insights

U0126, a MAPK pathway inhibitor, impacts cell functions and homeostasis. This review explores its cancer-inhibiting potential and mechanisms, suggesting it as a novel cancer treatment strategy.

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Oncology

Background:

  • The MAPK signaling pathway regulates critical cellular processes including differentiation, growth, autophagy, apoptosis, and stress responses.
  • U0126 is a known inhibitor of the MAPK pathway, crucial for maintaining cellular homeostasis.
  • While U0126 shows potential in inhibiting various cancers, its precise mechanisms in different cancer types remain incompletely understood.

Purpose of the Study:

  • To review recent research on the diverse applications of U0126.
  • To elucidate the role and mechanisms of U0126 in various cancer cell types.
  • To discuss the potential of U0126 as a novel therapeutic agent for cancer treatment by suppressing the MAPK pathway.

Main Methods:

  • Literature review of recent and relevant studies on U0126.
  • Analysis of U0126's functions and mechanisms in different cancer contexts.
  • Discussion of laboratory-researched functions of U0126.

Main Results:

  • U0126 influences multiple biological processes vital for cellular balance.
  • The review consolidates current knowledge on U0126's effects across different cancer types.
  • Identified laboratory functions of U0126 provide insights into its anti-cancer properties.

Conclusions:

  • U0126 plays a significant role in cellular homeostasis through MAPK pathway inhibition.
  • Further research into U0126's mechanisms can clarify its therapeutic potential in oncology.
  • Targeting the MAPK pathway with U0126 presents a promising novel strategy for cancer treatment.
Keywords:
MAPK inhibitorsMAPK signal pathwayU0126cancercancer therapy

More Related Videos

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

8.0K
Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

6.1K

Related Concept Videos

MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.9K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.4K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
8.7K
cAMP-dependent Protein Kinase Pathways01:25

cAMP-dependent Protein Kinase Pathways

Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
6.5K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
9.2K